热门资讯> 正文
Amphastar报告FDA批准特立帕肽注射剂
2025-12-15 19:33
- Amphastar制药(AMPH) 0
- 礼来(LLY) 0
- 艾昆纬(IQV) 0
- Amphastar Pharmaceuticals (AMPH) said that the U.S. Food and Drug Administration has approved the company's abbreviated new drug application for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen.
- The FDA determined that Amphastar's teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly's (LLY) FORTEO.
- According to IQVIA, the overall U.S. sales for teriparatide injection were approximately $585 million for the 12 months ended September 30, 2025.
- Amphastar (AMPH) plans to launch its teriparatide injection by the end of the year.
- Amphastar Pharmaceuticals (AMPH) +4.8% premarket.
More on Amphastar Pharmaceuticals
- Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies London Healthcare Conference 2025 - Slideshow
- Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript
- After Protracted Sell-Off, Amphastar Looks Like A Value Pick
- Amphastar Pharmaceuticals Q3 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Amphastar Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
